Jinsong Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jinsong Zhang has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Jianqing Gao
Zhejiang University
3 shared publications Jiawen Wang
State Key Laboratory of Advanced Drug Delivery and Release Systems, School of Pharmacy, Zhejiang University, Hangzhou, China
3 shared publications- Tianyuan Zhang
College of Pharmaceutical Sciences Zhejiang University Hangzhou 310058 China
3 shared publications Honghui Wu
State Key Laboratory of Advanced Drug Delivery and Release Systems, School of Pharmacy, Zhejiang University, Hangzhou, China
2 shared publications- Ruyi Lin
State Key Laboratory of Advanced Drug Delivery and Release Systems, School of Pharmacy, Zhejiang University, Hangzhou, China
2 shared publications - Donghang Xu
Department of Pharmacy, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
- 5 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9412
Airway administered artificial mitochondria-enriched nanovesicles for efficient and selective mitochondria transfer to intervene in pulmonary fibrosis
Mitochondrial transplantation is a promising therapeutic approach involving the transfer of exogenous mitochondria into diseased cells to restore impaired mitochondrial homeostasis. However, its clinical translation is severely limited by the lack of efficient methods for precise and potent mitochondria transfer. Inspired by natural mitochondria-containing vesicles, we develop mesenchymal stem cell-derived biomimetic nanovesicles with high mitochondrial loading capacity and augmented extracellular mitochondrial stability. These nanovesicles exhibit an ability to efficiently and selectively deliver mitochondrial cargo to injured cells, which is potentially ascribed to the specific interaction between very late antigen-5 on the nanovesicle surface and pathologically upregulated fibronectin on injured cells. In a mouse pulmonary fibrosis model, these nanovesicles successfully deliver healthy mitochondria to injured lung epithelial cells through airway administration, resulting in a significant reduction in fibrotic progression. This study introduces a design of mitochondria-enriched biomimetic nanovesicles for effective and targeted mitochondria transfer, offering a nanotechnology-based strategy to advance mitochondrial transplantation therapy.
- 5 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9412
Open AccessAirway administered artificial mitochondria-enriched nanovesicles for efficient and selective mitochondria transfer to intervene in pulmonary fibrosis
Mitochondrial transplantation is a promising therapeutic approach involving the transfer of exogenous mitochondria into diseased cells to restore impaired mitochondrial homeostasis. However, its clinical translation is severely limited by the lack of efficient methods for precise and potent mitochondria transfer. Inspired by natural mitochondria-containing vesicles, we develop mesenchymal stem cell-derived biomimetic nanovesicles with high mitochondrial loading capacity and augmented extracellular mitochondrial stability. These nanovesicles exhibit an ability to efficiently and selectively deliver mitochondrial cargo to injured cells, which is potentially ascribed to the specific interaction between very late antigen-5 on the nanovesicle surface and pathologically upregulated fibronectin on injured cells. In a mouse pulmonary fibrosis model, these nanovesicles successfully deliver healthy mitochondria to injured lung epithelial cells through airway administration, resulting in a significant reduction in fibrotic progression. This study introduces a design of mitochondria-enriched biomimetic nanovesicles for effective and targeted mitochondria transfer, offering a nanotechnology-based strategy to advance mitochondrial transplantation therapy.
- Open Access
- 3 February 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (7) , 4128-4146
Unveiling the bioactive landscape of drug inactive ingredients (DIGs) using deep transfer learning
- 3 February 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (7) , 4128-4146
Open AccessUnveiling the bioactive landscape of drug inactive ingredients (DIGs) using deep transfer learning
- Open Access
- 9 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10980
Periodic asymmetric field enhances electrofusion of nanoscale lipid systems
Electrofusion is a widely used technique for inducing membrane merging in biological systems, with applications ranging from hybrid lipid architectures to therapeutic delivery. However, the direct application of conventional electrofusion to advanced nanoscale drug carriers, such as cell membrane hybrid LNPs (cLNPs), faces challenges due to diminished dielectric response and uncontrolled particle dynamics. To address these limitations, we report a periodic asymmetric field (PAF) strategy that combines microfluidic flow with periodic electric fields to enhance nanoscale electrofusion. We systemically investigate the underlying mechanisms using computational fluid dynamics simulations, and subsequently fabricate and optimize a PAF-guided microfluidic electrofusion device (PAF-MED) for the controlled synthesis of cLNPs. These PAF-MED-synthesized cLNPs demonstrate improved fusion efficiency, augmented targeting capability, and superior therapeutic efficacy in bleomycin-induced pulmonary fibrosis murine models. This approach represents a unique advancement in the nanoscale manipulation of drug carriers towards better bio-functionality and reproducibility beyond conventional capability of electrofusion.
- 9 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10980
Open AccessPeriodic asymmetric field enhances electrofusion of nanoscale lipid systems
Electrofusion is a widely used technique for inducing membrane merging in biological systems, with applications ranging from hybrid lipid architectures to therapeutic delivery. However, the direct application of conventional electrofusion to advanced nanoscale drug carriers, such as cell membrane hybrid LNPs (cLNPs), faces challenges due to diminished dielectric response and uncontrolled particle dynamics. To address these limitations, we report a periodic asymmetric field (PAF) strategy that combines microfluidic flow with periodic electric fields to enhance nanoscale electrofusion. We systemically investigate the underlying mechanisms using computational fluid dynamics simulations, and subsequently fabricate and optimize a PAF-guided microfluidic electrofusion device (PAF-MED) for the controlled synthesis of cLNPs. These PAF-MED-synthesized cLNPs demonstrate improved fusion efficiency, augmented targeting capability, and superior therapeutic efficacy in bleomycin-induced pulmonary fibrosis murine models. This approach represents a unique advancement in the nanoscale manipulation of drug carriers towards better bio-functionality and reproducibility beyond conventional capability of electrofusion.
- 25 February 2024
- Published by Wiley in Biotechnology Journal
- Vol. 19 (2) , e2300174
A large‐scale production of mesenchymal stem cells and their exosomes for an efficient treatment against lung inflammation
Mesenchymal stem cells (MSCs) and their produced exosomes have demonstrated inherent capabilities of inflammation‐guided targeting and inflammatory modulation, inspiring their potential applications as biologic agents for inflammatory treatments. However, the clinical applications of stem cell therapies are currently restricted by several challenges, and one of them is the mass production of stem cells to satisfy the therapeutic demands in the clinical bench. Herein, a production of human amnion‐derived MSCs (hMSCs) at a scale of over 1 × 109 cells per batch was reported using a three‐dimensional (3D) culture technology based on microcarriers coupled with a spinner bioreactor system. The present study revealed that this large‐scale production technology improved the inflammation‐guided migration and the inflammatory suppression of hMSCs, without altering their major properties as stem cells. Moreover, these large‐scale produced hMSCs showed an efficient treatment against the lipopolysaccharide (LPS)‐induced lung inflammation in mice models. Notably, exosomes collected from these large‐scale produced hMSCs were observed to inherit the efficient inflammatory suppression capability of hMSCs. The present study showed that 3D culture technology using microcarriers coupled with a spinner bioreactor system can be a promising strategy for the large‐scale expansion of hMSCs with improved anti‐inflammation capability, as well as their secreted exosomes.
- 25 February 2024
- Published by Wiley in Biotechnology Journal
- Vol. 19 (2) , e2300174
A large‐scale production of mesenchymal stem cells and their exosomes for an efficient treatment against lung inflammation
Mesenchymal stem cells (MSCs) and their produced exosomes have demonstrated inherent capabilities of inflammation‐guided targeting and inflammatory modulation, inspiring their potential applications as biologic agents for inflammatory treatments. However, the clinical applications of stem cell therapies are currently restricted by several challenges, and one of them is the mass production of stem cells to satisfy the therapeutic demands in the clinical bench. Herein, a production of human amnion‐derived MSCs (hMSCs) at a scale of over 1 × 109 cells per batch was reported using a three‐dimensional (3D) culture technology based on microcarriers coupled with a spinner bioreactor system. The present study revealed that this large‐scale production technology improved the inflammation‐guided migration and the inflammatory suppression of hMSCs, without altering their major properties as stem cells. Moreover, these large‐scale produced hMSCs showed an efficient treatment against the lipopolysaccharide (LPS)‐induced lung inflammation in mice models. Notably, exosomes collected from these large‐scale produced hMSCs were observed to inherit the efficient inflammatory suppression capability of hMSCs. The present study showed that 3D culture technology using microcarriers coupled with a spinner bioreactor system can be a promising strategy for the large‐scale expansion of hMSCs with improved anti‐inflammation capability, as well as their secreted exosomes.